Oral phenylbutyrate vs placebo
Adverse events related to treatment · children with SMA type II
Oral phenylbutyrate probably leads to higher adverse events related to treatment compared with placebo (moderate certainty).
1 finding from 1 review
- RR 3.1 [1.25, 7.84]1 study · 107 participantsModerate